Profilo
Konrad Glund is the founder of Vivoryon Therapeutics NV, which was founded in 1997.
He held the title of Chief Executive Officer from 2006 to 2018.
Dr. Glund is also the founder of IFB Halle GmbH.
He previously worked as Vice President-Corporate Development at Prosidion Ltd.
and as a Principal at Martin-Luther-Universität Halle-Wittenberg.
Dr. Glund earned a doctorate degree from Martin-Luther-Universität Halle-Wittenberg.
Precedenti posizioni note di Konrad Glund
Società | Posizione | Fine |
---|---|---|
VIVORYON THERAPEUTICS N.V. | Amministratore Delegato | 30/04/2018 |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | - |
Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
IFB Halle GmbH | Amministratore Delegato | - |
Formazione di Konrad Glund
Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
VIVORYON THERAPEUTICS N.V. | Health Technology |
Aziende private | 2 |
---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
IFB Halle GmbH |
- Borsa valori
- Insiders
- Konrad Glund